To investigate the relationship between central venous pressure (CVP) at presentation to the emergency room (ER) and the risk of cardiac rehospitalization and mortality in patients with decompensated heart failure (DHF).
Introduction
Decompensated heart failure (DHF) is a major and growing problem in the health care system, with approximately one million hospitalizations occurring annually in the US alone. 1, 2 Recent data have shown that a substantial proportion of DHF hospitalizations are caused primarily by volume overload, rather than by low cardiac output. 3, 4 High right atrial pressure, as measured using a central venous catheter, indicates coexistent elevated right and frequently left-sided pressure and is associated with signs (weight gain and peripheral oedema) and symptoms (dyspnoea and exercise intolerance) of pulmonary and systemic congestion. 4 -6 Venous congestion has been recently demonstrated as a main predictor of organ injury and death. 7, 8 Unfortunately, clinical assessment of increased venous congestion, such as jugular vein distension had been shown to be an unreliable tool compared with the invasive measurement of central venous pressure (CVP). 9, 10 Although invasive measurement of CVP is the current 'gold-standard' for measuring venous congestion, it remains costly and related to potential major adverse events and therefore is not feasible in the vast majority of patients. 11 Controlled compression sonography at the forearm presents an attractive non-invasive alternative for the measurement of CVP. 12, 13 Using this novel technique of CVP measurement, we examined patients with DHF immediately after presentation to the emergency room (ER). Our aim was to establish new insights into the pathophysiology of DHF and to evaluate the relationship between CVP and the two most important clinical outcomes in DHF; cardiac rehospitalization and death.
Methods Patients
We analysed patients presenting with DHF to the ER of the University Hospital of Basel between April 2006 and September 2008. Patients .18 years of age who presented with shortness of breath as a primary symptom and a reasonable clinical suspicion of DHF were enrolled whenever CVP measurements were promptly available (8:00 a.m.-6:00 p.m.). To avoid time-bias, e.g. CVP interaction with therapy, CVP measurement within 1 h after enrolment was targeted. Patients underwent an initial clinical assessment that included clinical history, physical examination, electrocardiography, pulse oximetry, blood tests including B-type natriuretic peptide (BNP), chest X-ray, non-invasive ultrasound measurement of CVP at presentation to the ER, and echocardiography (when indicated). Before discharge, physical examination, blood tests, and measurement of CVP were repeated. The study was approved by the Ethics Committee of the University of Basel. All patients gave written informed consent to participate in the study. The study conformed to the principles outlined in the Declaration of Helsinki.
Non-invasive measurement of central venous pressure
Ultrasound imaging was performed by two experienced investigators (C.T. and M.A.) using a HDI 5000 duplex device (Philips, Best, the Netherlands) with a 12-5 MHz linear array transducer (SonoCT, XRes) and an attached pressure manometer (PPM0310, Baumann, Muensingen, Switzerland). The manometer consists of a translucent silicon membrane (MVQ, Angst and Pfister AG, Zurich, Switzerland) connected to a commercially available pressure metre (Bourdon Haenni AG, Jegenstorf, Switzerland) with a flexible pressure tubing. Patients were placed in a comfortable supine position in a temperature-controlled room and measurements were done at the forearm placed on the bed. After zero adjustment, slowly increasing pressure was applied by the transducer until complete compression of the selected superficial forearm vein (preferentially the distal cephalic vein) was achieved. The pressure when the vein completely collapsed corresponds to the intravasal venous pressure and was measured continuously. The difference between the level of the sonographic measurement point and the right atrial level (median 8 cm, interquartile range 5-10 cm) was subtracted from the crude values for correction of the blood column height. Non-invasive CVP can be adequately obtained within less than 4 min. 12 In healthy subjects as well as in intensive care unit patients, a high correlation and negligible difference between the non-invasive and the invasive measurement of CVP has been demonstrated.
12,13

Endpoint assessment
The primary endpoints in the present study consisted of time to cardiac rehospitalization and cardiac or all-cause mortality as a function of CVP measured at presentation to the ER. Mortality and morbidity data were attained by telephone interview in a blinded fashion by physicians who were not involved in patient care and by collection of all available medical records pertaining to each patient. All rehospitalizations and deaths were classified as being due to cardiac or non-cardiac causes according to the most proximate cause by a clinical events committee whose members were blinded to CVP results.
Statistical analysis
Data analysis was performed using SPSS 16 
Results
Non-invasive measurement of CVP was performed in 100 patients within 35 min (range 6 -35) after enrolment. During a median follow-up of 12 months (range 0-20 months), 25 (25%) patients were rehospitalized for cardiac reasons (DHF of any cardiac aetiology) and 33 patients (33%) died (26 cardiac and 7 noncardiac deaths). Patient characteristics at presentation according to subsequent cardiac rehospitalization and all-cause mortality are shown in Table 1 .
Central venous pressure at presentation was 16.3 + 6.9 cm H 2 O in patients with cardiac rehospitalization and 12.8 + 6.9 cm H 2 O in patients without cardiac rehospitalization during follow-up (P ¼ 0.029). Rehospitalized patients were younger and presented with a higher glomerular filtration rate but had higher potassium levels at initial presentation than non-rehospitalized patients.
Multivariate analysis showed that CVP at presentation independently predicted cardiac rehospitalization rates ( Table 2) . Kaplan -Meier curves confirmed a stepwise increase in cardiac rehospitalization with higher CVP levels (log-rank P ¼ 0.015) ( Figure 1A ). Calculated mean time to cardiac rehospitalization was 19.2 (95% CI 16.5-22), 13.7 (95% CI 11.9-15.4), and 6.3 (95% CI 2.7 -9.8) months for initial low, intermediate, and high CVP levels, respectively.
Relationships between all-cause mortality and CVP are displayed in Tables 1 and 2 . Univariate analysis displayed no difference in CVP between patients who died or survived (13.7 + 7.0 vs. 13.5 + 7.3 cm H 2 O, P ¼ 0.863). In contrast, higher age, creatinine, BUN, CK, BNP levels, lower eGFR, and BMI were associated with a grave outcome ( Table 1) . In multivariate analysis, only BNP at presentation remained an independent predictor of all-cause mortality (P ¼ 0.036), whereas CVP at presentation did not independently predict all-cause mortality (P ¼ 0.979) ( Table 2) . Corresponding hazard ratios of the multivariate analyses are displayed in Table 2 . Kaplan-Meier curves are plotted in Figure 1B and once again displayed no association between CVP levels and To address whether therapy differed between patients with different CVP levels, we compared clinical data at presentation and discharge according to initial CVP levels (Tables 4 and 5). Though a significantly greater CVP reduction occurred in patients with initially high CVP levels, no significant difference in initial or discharge medication, inpatient BW reduction, or inpatient days was detectable.
Discussion
Using a novel technique of non-invasive CVP measurement, we investigated the relationship between initial CVP levels and the risk of cardiac rehospitalization and mortality in patients with DHF.
We report four major findings. First, CVP at presentation is an independent determinant for cardiac rehospitalization. Second, CVP at presentation is not related to subsequent cardiac or all-cause mortality. Third, CVP and BW reduction during hospitalization did not predict cardiac rehospitalization. Fourth, CVP and BW reduction during hospitalization did not predict cardiac or all-cause death. Therefore, this study adds important new insights into the concept that different pathophysiological aspects might be major players for cardiac rehospitalization and death in patients with DHF.
Many (non-cardiac) factors may contribute to the relation between CVP in DHF and morbidity. Left and right ventricular dysfunction resulting in high ventricular filling pressures, excessive neurohumoral activation with elevated circulating or tissue levels of norepinephrine, angiotensin II, and aldosterone, patient's noncompliance to medication, and sodium and/or fluid restriction might increase (alone or in concert) CVP which reflects the impaired performance of the failing heart. In fact, continuous monitoring of right ventricular haemodynamics in chronic heart failure patients demonstrated that in 9 out of 12 patients, a .20% increase in right ventricular pressure occurred before volume-overload exacerbations caused subsequent hospitalization.
14 Likewise, an increase in BW in the immediate pre-hospitalization period was observed.
-17
Thus, our observation that CVP predicts subsequent cardiac rehospitalization suggests that CVP at presentation might reflect the patient's 'tolerable reserve' with respect to e.g. fluid-overload ultimately leading to rehospitalization. It is important to note that increases in BW in the post-discharge period are a major predictor for cardiac hospitalization but not for mortality. 17 This is in line with our finding that CVP predicts cardiac rehospitalization but not mortality. Analysing 2557 patients with a mixture of cardiovascular diseases who underwent right heart catheterization, Damman et al. 8 showed that increased CVP is associated with mortality.
Several population characteristics may account to these contrasting results. First, the patients analysed by Damman et al. were substantially younger (59 + 15 vs. 78 + 11 years) and in only 16%, acute or chronic heart failure was the predominant reason for right heart catheterization. In addition, our patients had a considerably higher number of comorbidities (e.g. 42 vs. 9% diabetes mellitus, 78 vs. 20% hypertension, and 38 vs. 6% dyslipidaemia) and an extended medical therapy (e.g. 85 vs. 42% diuretics and 60 vs. 28% beta-blockers). Competing, non-cardiac deaths might have masked an association between CVP and mortality in our study, a larger study with a longer follow-up period might reveal an association between CVP level and all-cause mortality. However, from a clinical point of view, it is reasonable that elevated CVP levels might be a Values are mean + SD or n (%). Significant P-values are given in italics. CVP, central venous pressure; BW, body weight; ACE, angiotensin-converting enzyme.
surrogate of predisposition to further congestion and therefore affect short-term hospitalization rates more than long-term mortality.
The observation that CVP predicts cardiac rehospitalization but not mortality in patients with DHF might have important clinical implications. The cardinal manifestations of DHF are pulmonary congestion and fluid overload, which may lead to dyspnoea, peripheral oedema, and limited exercise tolerance. 15, 18, 19 Thus, therapy to reduce volume overload is the cornerstone of any successful treatment and leads to marked improvement in signs and symptoms of congestion. 6, 20 Our patients experienced significant reductions in both BW and CVP, but this reduction in (intravascular) volume was not associated with reductions in cardiac rehospitalization or mortality. Accordingly, growing evidence indicates that fluid removal itself may not necessarily prevent rehospitalizations or reduce mortality. 17, 21 For example, in the EVEREST study Values are mean + SD or n (%). Significant P-value is given in italics. ACE, angiotensin converting enzyme; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; BMI, body-mass index, eGFR, estimated glomerular filtration rate (Cockroft -Gault formula); BUN, blood urea nitrogen; BNP, B-type natriuretic peptide; CK, creatinine kinase.
(Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan), rapid and sustained decreases in BW throughout hospitalization and after discharge did not result in mortality benefits. 17 Diuretics are known to effectively remove fluid but may worsen renal function and further activate neurohormones, thus offsetting the positive effect of therapeutic intervention on outcomes. 22, 23 In particular, older patients, as seen in our study, demonstrate that survival quality, not survival time, is the most important measure of benefit and represents a major therapy target in patients with advanced heart failure. Our data show that CVP measurement, immediately upon presentation to the ER may help identify patients at higher risk for cardiac rehospitalization and may be used to better tailor therapy and patient surveillance in order to avoid early cardiac rehospitalizations. However, the optimal therapy and surveillance strategy are yet to be established. For example, titration of specific heart failure therapies guided by BNP levels (an indicator of elevated ventricular filling pressures) has resulted in improved outcomes in selected groups. 24, 25 Further randomized controlled trials are needed to confirm (or reject) our hypothesis that CVP measurements performed promptly after presentation provide relevant clinical information for potential therapeutic intervention and subsequent outcome. Nevertheless, this study reveals important new insights into the pathophysiology behind the two most important clinical outcomes in DHF: cardiac rehospitalization and death. This observation also raises concern regarding the increasing use of death and cardiac rehospitalization as a combined endpoint in clinical trials enrolling DHF patients. Namely, the inclusion of factors in the composite endpoint that are not similarly affected by the intervention may actually 'dilute' the observed treatment effect and decrease the overall statistical power.
Limitations
There are several limitations to our study. First, we used a novel technique to measure CVP. Accordingly, only limited clinical experience exists with this technique. However, non-invasive controlled compression sonography of the forearm has been demonstrated to be accurate in measuring CVP with a high correlation between invasive and non-invasive ultrasound CVP measurement over a wide range of pressures, not only in a highly selected but also in a more generalized setting. 12,13 Second, we did not enrol consecutive patients with DHF and a selection bias may have occurred. The decision for enrolment was made blinded to patients' clinical characteristics and was only limited by the prompt availability of the CVP measurement (ultrasound machine and examiner). In fact, the baseline characteristics of our study population were similar to the baseline characteristics of a previously published study of 217 patients with DHF presenting at the emergency department of the University Hospital of Basel over 1 year. 26 Third, our sample size is relatively small. Nevertheless, the study was sufficiently powered to demonstrate a clinically meaningful difference in cardiac rehospitalization rates according to CVP levels and all-cause mortality according to BNP levels, representing a well-known prognostic parameter for mortality in this setting. 27 -30 Fourth, several different CVP level categories could have been used. However, no consensus for CVP graduation exists and therefore we used predefined CVP levels according to the literature and the expected range of CVP values.
Conclusions
Central venous pressure measured at presentation to the ER in patients with DHF is an independent determinant of cardiac rehospitalization but not of cardiac or all-cause mortality. This study adds important new insights to the concept that different pathophysiological aspects seem to underlie the two most important clinical outcomes in DHF: cardiac rehospitalization and death. Compression sonography at the forearm represents an attractive non-invasive alternative for measuring CVP, which might be used to guide subsequent therapy and follow-up.
